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Introduction
Th   e management of breast cancer patients is still guided 
based on a constellation of clinicopathological features, 
including prognostic markers derived from careful histo-
pathological analysis of tumours, namely tumour size, 
histological grade, presence of lymph node metastasis 
and vascular invasion [1-3]. Despite the huge amount of 
resources allocated to translational research endeavours, 
only three predictive markers are utilised to deﬁ  ne the 
therapy of breast cancer patients: oestrogen receptor 
(ER) and progesterone receptor (PR), the predictive 
markers of response to endocrine therapy, and human 
epidermal growth factor receptor 2 (HER2), the mole-
cular target of trastuzumab and lapatinib. Th  ese 
parameters are then used in conjunction either in the 
form of guidelines (for example, St Gallen’s consensus 
criteria) or included in multivariable algorithms (for 
example, Adjuvant!Online) for clinical decision making 
[1-3]. Albeit seemingly simplistic, this approach has been 
shown to be clinically relevant, given that predictions 
made with Adjuvant!Online do correlate with the actual 
outcome of breast cancer patients [4], and, most 
importantly, the use of this framework to deﬁ  ne  the 
systemic therapy of breast cancer patients has contri-
buted to the steady decline in the mortality of breast 
cancer patients [5]. Although eﬀ  ective, this approach is 
not suﬃ   cient for the potential of individualised therapy 
to be realised.
Th  e promise of high throughput technologies, and in 
particular of gene expression proﬁ  ling with microarrays, 
has been of apocalyptic dimensions [6-9]. Th  e  objectivity 
of the methodology coupled with the elaborate, if not 
mind boggling [10], bioinformatic approaches to answer 
clinically relevant questions have led some of the 
proponents of this technology to compare histopathology 
with some rituals practiced by ancient tribes [7], and 
some experts in the ﬁ  eld predicted back in 2000 that 
microarrays would make conventional diagnostic tech-
niques obsolete [6].
Microarrays and their derivatives have undoubtedly 
contributed to our understanding of breast cancer (for 
reviews, see [1,2]). Th   ey have provided direct evidence to 
demonstrate that breast cancer is a heterogeneous 
disease at the molecular level [11], that ER-positive and 
-negative diseases are fundamentally diﬀ  erent  [11-14], 
that molecular subtypes of breast cancer do exist 
[11,15-18], and that some special histological types of 
breast cancer are distinct entities at the molecular level 
[19-22]. Furthermore, they have led to the development 
of a molecular taxonomy that is currently being tested in 
clinical trials [16], and of prognostic ‘gene signatures’, 
some of which have already been approved by the US 
Food and Drug Administration [1,2,13,23].
Molecular taxonomy
From a conceptual standpoint, the development of a 
molecular taxonomy [11,15-18] for breast cancer has 
reshaped the way breast cancer is perceived. According 
to this classiﬁ  cation, breast cancers can be subdivided 
into luminal tumours, which are ER-positive, express ER-
related genes and are reported to be subclassiﬁ  ed into A 
and B according to the expression level of proliferation-
related genes [1,2,15,16,24]; HER2 tumours, which ex-
press HER2 and genes related to the HER2 amplicon; 
normal breast-like cancers, which are still poorly under-
stood and are reported to express genes usually found in 
normal breast samples; and basal-like cancers, which 
largely lack expression of ER, PR and HER2, and express 
genes usually found in basal/myoepithelial cells of the 
breast [1,2,11,15-18,24]. Th   e terms luminal A, luminal B, 
normal breast-like, basal-like and HER2 have become 
part of our lexicon. Th  e approach pioneered by the 
Stanford group, however, has some important limitations. 
First, our recent re-analysis of the methods for the 
identiﬁ  cation of the molecular subtypes of breast cancer  © 2010 BioMed Central Ltd
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basal-like cancers can be reliably identiﬁ   ed [25]; the 
classiﬁ  cation of samples into the other molecular sub-
types is dependent on the methods used for the 
classiﬁ   cation of the samples and the agreement rates 
between diﬀ   erent methods is modest [25,26]. In fact, 
even when the authors of the molecular taxonomy them-
selves classiﬁ  ed the same cohort of breast cancer patients 
(that is, NKI-295 [23]) using two diﬀ  erent  methods 
[27,28], one by Sorlie and colleagues [17,27] and the 
other by Hu and colleagues [15,28], the agreement was 
only moderate (Kappa scores = 0.527 (95% conﬁ  dence 
interval 0.456 to 0.597)). Second, there are several lines of 
evidence to suggest that normal breast-like cancers may 
constitute an artefact of gene expression proﬁ  ling (that is, 
samples with a disproportionately high content of normal 
breast epithelial cells and stromal cells) [16,25]. Th  ird, 
given that the subdivision of luminal tumours into A and 
B is driven by the levels of expression of proliferation-
related genes and that several studies have demonstrated 
that proliferation in ER-positive cancers is a continuum 
rather than a bi-modal distribution, this subclassiﬁ  cation 
of luminal cancers is likely to be arbitrary [1,2,12,14,  16, 
25,  29]. Fourth, the HER2 molecular subtype neither com-
prises all cases classiﬁ  ed as HER2-positive with clinically 
validated methods (that is, immunohistochemical analysis 
and chromogenic/ﬂ  uorescence in situ hybridisa tion)  and 
not all HER2-positive cancers by clinical methods are 
classiﬁ   ed as HER2 subtype by microarrays [16,25,30]. 
Th   erefore, for the microarray-based molecular taxonomy 
of breast cancer to be incorporated into clinical practice, 
standardisation of the deﬁ  nitions and the methodologies 
for the identiﬁ   cation of the molecular subtypes and 
prospective clinical trials to validate the contribution of 
these ﬁ  ve molecular subtypes in addition to the current 
clinicopathological parameters for prognosis prediction 
of breast cancer patients are required, and this is yet to be 
achieved.
Prognostic gene signatures
Th  e development of microarray-based prognostic gene 
signatures was heralded as a major breakthrough for the 
management of breast cancer patients [1,2,8,9,13,31-33]. 
It was thought then that these signatures would provide a 
more objective assessment of the risk of relapse of breast 
cancer patients and would be more reproducible than the 
methods currently used [1,2,8,9,33]. Th  e  ﬁ  rst prognostic 
gene signatures (that is, the 70-gene signature also known 
as Mammaprint® [13], and the 76-gene signature [31]) 
were developed to be applied to all breast cancer patients. 
Th   eir performance in the training and validation datasets 
demonstrated objectively that the prognostic information 
provided by these signatures is indeed independent of the 
information provided by tumour size, presence of lymph 
node metastasis and histological grade [1,2,32]. Subse-
quent to these initial stories of success, several groups 
developed their own prognostic signatures either employ-
ing bottom-up or top-down approaches (for reviews, see 
[1,2]). In addition, independent groups developed micro-
array signatures to capture the information provided by 
histological grade [34,35].
Following the initial enthusiasm with microarray-based 
prognostic gene signatures, re-analyses of the initial 
studies on cancer prognosis with microarrays have 
revealed that the overlap between gene signatures was 
negligible; that these ﬁ  rst generation signatures were not 
stable in terms of their gene composition [36,37]; and 
that these gene signatures were time dependent (that is, 
their prognostic power is substantially reduced from 5 to 
10 years of follow-up) [1,2,36-38]. Th  ese observations 
have led to a wave of (over)scepticism, with an expert in 
the ﬁ  eld of biomarker discovery and validation stating 
that ‘… on close scrutiny, in ﬁ   ve of the seven largest 
studies on cancer prognosis, this technology performs no 
better than ﬂ  ipping a coin. Th   e other two studies barely 
beat horoscopes” [39]. Fortunately, with the greater 
availability of microarray datasets in public repositories, 
meta-analyses performed by independent groups 
revealed that diﬀ  erent gene signatures identify similar 
groups of patients as of poor outcome; that the assign-
ment of cases as of poor outcome is based on the 
expression of proliferation-related genes; that these ﬁ  rst 
generation signatures only have discriminatory power in 
ER-positive disease; and that proliferation is perhaps the 
strongest determinant of outcome in ER-positive disease 
[12,14,28,40].
In parallel with the development of microarray-based 
gene signatures, a 21-gene signature based on quanti-
tative real time RT-PCR was developed through a re-
analysis of microarray datasets and a review of the 
literature [41,42]. Th   is signature, named OncotypeDXTM 
(Genomic Health, Redwood, CA, USA) was developed 
and validated through a retrospective analysis of 
formalin-ﬁ  xed,  paraﬃ     n-embedded material from the 
prospective clinical trials B-20 and B-14 [41,42] (for 
reviews, see [43,44]). OncotypeDxTM has been shown to 
be prognostic in ER-positive tumours, but also identiﬁ  es 
those patients who are likely to beneﬁ  t most from chemo-
therapy [41-44]. Th  erefore, it can be used to determine 
which patients should receive endocrine therapy or a 
combination of endocrine plus chemotherapy. Th   is test is 
only oﬀ  ered for central analysis in the Genomic Health 
laboratories and has been shown to be robust, so much 
so that it has been recommended for the management of 
breast cancer patients by the American Society of 
Clinical Oncology (ASCO) guidelines on the use of 
tumour markers in breast cancer, and in the National 
Comprehensive Cancer Network (NCCN) guidelines for 
Weigelt and Reis-Filho Breast Cancer Research 2010, 12(Suppl 4):S5
http://breast-cancer-research.com/supplements/12/S4/S5
Page 2 of 4breast cancer treatment, as a predictor of recurrence for 
ER-positive, lymph node-negative breast cancer patients. 
Despite the important contribution of OncotypeDxTM for 
the management of breast cancer patients, it should be 
noted that this test is meant to be used in conjunction 
with the clinicopathological prognostic factors [2,41-44]. 
Furthermore, there is evidence to suggest that the 
prognostic power of OncotypeDxTM, in a way akin to the 
other ﬁ  rst generation signatures, largely if not exclusively 
stems from the quantitative analysis of the levels of 
expression of proliferation-related genes [1,2,14].
Despite the controversies above, the question that 
remains germane is whether molecular proﬁ  ling oﬀ  ers 
more than the information provided by clinicopatho-
logical parameters and a handful of immunohisto-
chemical markers. Th   is was in part addressed by Dunkler 
and colleagues [45], who re-analysed the data from the 
cohort employed to validate the 70-gene signature and 
demonstrated that the contribution of this signature to 
the prognostication of breast cancer patients above and 
beyond that oﬀ   ered by the clinicopathological para-
meters was minimal. Furthermore, a recent comparison 
of the prognostic information provided by OncotypeDxTM 
or four immunohistochemical markers (that is, ER, PR, 
HER2 and Ki67 - a proliferation marker) semi-quanti  ta-
tively assessed in the material from the ATAC (Arimidex, 
Tamoxifen, Alone or in Combination) prospective trial 
demonstrated that these four markers would at least be 
equivalent to OncotypeDxTM [46].
Conclusion
Taken together, it would be fair to say that, currently, 
molecular proﬁ  ling does provide additional prog  nostic 
and to some extent predictive information to the current 
clinicopathological features and immunohisto  chemical 
markers routinely used. However, this infor  mation 
beneﬁ   ts a limited number of patients, is restricted to 
patients with ER-positive cancers, and seems only to 
constitute a reproducible and quantitative analysis of 
tumour cell proliferation. Th   erefore, pathologists should 
strive for developing robust and reproducible methods 
for the assessment of proliferation (for example, a stan-
dard  ised Ki67 immunohistochemical protocol and 
scoring system). Although the enthusiasm with micro-
arrays has waned, this technology has provided an incre-
mental step towards the individualisation of therapy for 
breast cancer patients. It is probable that this goal will be 
achieved through the integration of diﬀ  erent layers of 
high-throughout data (that is, transcriptomics, proteo-
mics, functional genomics). Furthermore, the develop-
ment of massively parallel sequencing approaches [47,48] 
and their application to the study of breast cancer is likely 
to provide information that will constitute another 
quantum leap in the way we perceive this complex 
disease, and help develop more accurate prognostic and 
predictive tests to each subgroup/subtype of breast 
cancers.
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